The p53 protein activates promoters containing p53 binding sites, and it represses other promoters. We examined the eect of p53 on bcl-2 expression in both the DHL-4 B cell line and the K562 erythroleukemia line. Transient transfection analyses revealed that wildtype p53 repressed the bcl-2 full-length promoter. The region of the bcl-2 promoter that was responsive to p53 was mapped to the bcl-2 P2 minimal promoter region, and we showed that p53 and the TATA binding protein bound to the bcl-2 TATA sequence. The TATA binding protein, p53, histone deacetylase-1 and mSin3a could be co-immunoprecipitated from K562 cell nuclear extract. The TATA binding protein and mSin3a could be recovered in a complex at the bcl-2 promoter TATA sequence, however, the formation of this complex was not dependent on the presence of p53. Treatment of K562 cells with the histone deacetylase inhibitor, trichostatin A, resulted in an increase in bcl-2 promoter activity whether p53 was present or not. Therefore, we demonstrated that p53 and the histone deacetylases repress the bcl-2 promoter independently. Similar results were obtained when endogenous bcl-2 mRNA or protein levels were measured in response to either p53 or trichostatin A, and p53 expression resulted in enhanced apoptosis. RNase protection assays demonstrated that transcription from the endogenous 3' bcl-2 promoter was decreased by p53. The regions of p53 that were required for repression of the bcl-2 promoter were de®ned. We conclude that the TATA sequence in the bcl-2 P2 minimal promoter is the target for repression by p53, and that the interaction between p53 and TBP is most likely responsible for the repression. Mutation of p53 may play a role in the up-regulation of bcl-2 expression in some B cell lymphomas. Oncogene (2001) 20, 240 ± 251.
Introduction
The control of cell survival is of central importance in tissues with high cell turnover such as the lymphoid system, and its disruption may be a critical step in tumorigenesis. Approximately 85% of follicular lymphomas and 20% of diuse B-cell lymphoma have a characteristic t(14;18) translocation (Yunis et al., 1987) . Bcl-2 was identi®ed at the interchromosomal breakpoint of the t(14;18) translocation (Cleary et al., 1986; Tsujimoto and Croce, 1986; Tsujimoto et al., 1985) . This translocation juxtaposes the bcl-2 gene normally located on chromosome 18q21 with the immunoglobulin heavy chain locus at chromosome 14q32, resulting in deregulated expression of the bcl-2 gene at the transcriptional level. The Bcl-2 protein has been found to protect against cell death in a variety of cell types (Yang and Korsmeyer, 1996) .
There are two sites of transcription initiation in the bcl-2 gene. The 5' bcl-2 promoter, P1, is located 1386 ± 1423 base pairs upstream of the translation start site (Seto et al., 1988) . This is a TATA-less, GC-rich promoter that displays several start sites. Another promoter, P2, is located 1.3 kilobases downstream from the ®rst one (3' promoter). We have characterized some of the regulatory regions of the bcl-2 promoter, including a cAMP-responsive element (CRE), which functions as a positive regulatory site (Ji et al., 1996; Wilson et al., 1996) . More recently we showed that AMyb up-regulated bcl-2 expression through a Cdx site in the bcl-2 promoter (Heckman et al., 2000) . Several negative regulatory sites have also been described in the bcl-2 promoter region. Our previous studies demonstrated that three p1 binding sites were negative regulators of bcl-2 expression in pre-B cells (Chen and Boxer, 1995) , while they were not functional in mature B cells. Another negative regulatory element is located upstream of the P2 promoter (Young and Korsmeyer, 1993) . It has been shown that a 195 bp region containing the TATA sequence in the bcl-2 promoter can mediate p53-dependent repression in lung cancer cells, but no p53-binding site was found in this region, and the mechanism for p53 regulation was not de®ned (Miyashita et al., 1994a) . Since regulation of bcl-2 expression by p53 is likely to be an important control mechanism, we sought to identify the region of the bcl-2 promoter that was required for this activity.
Many B cell lymphomas express elevated levels of Bcl-2. Mutation of p53 is common in lymphomas, and it may be involved in transformation to a higher grade. Low grade lymphomas also express mutated p53, although the number ranges from 3 ± 33% in dierent studies (Ilyas et al., 1996; Kramer et al., 1996; Nguyen et al., 1996; Said et al., 1992; Soini et al., 1992; Takano et al., 1997; Villeundas et al., 1992) and there is heterogeneity of expression (Barrans et al., 1995) . High level expression of MDM2 has also been reported in both low grade and aggressive B cell lymphomas (Moller et al., 1999; Watanabe et al., 1996) . One important function of MDM2 is to form a complex with p53, thus inhibiting its cellular functions and targeting it for degradation by ubiquitin-mediated proteolysis.
Wild-type p53 (wt-p53) is a nuclear phosphoprotein that acts as a tumor suppressor (Gotlieb and Oren, 1996) . It has been implicated in multiple cellular processes, including inhibition of proliferation of transformed cells (Xiong et al., 1993) , suppression of oncogenic transformation (Finlay et al., 1989) , and mediation of cell cycle arrest (Yew and Berk, 1992) and apoptosis (Yonish-Rouach et al., 1995) . Among these functions exhibited by p53, the mechanism of cell cycle control is well documented. However, the molecular mechanisms by which p53 mediates apoptosis are not completely understood. At the molecular level, p53 functions as a transcription factor. Wt-p53 can stimulate the expression of genes whose promoters contain p53-binding sites, i.e., bax, while some mutants of p53 appear to have lost this activity (Miyashita and Reed, 1995) . Wt-p53 can also repress a wide variety of cellular and viral promoters (Subler et al., 1992) , in particular some promoters that contain a TATA sequence (Mack et al., 1993) . Transcriptional repression has been shown to be involved in induction of apoptosis by p53. Some mutant forms of p53 that are incapable of inducing apoptosis are defective in repression but not in activation of transcription (Ryan and Vousden, 1998) . Deletion of the proline-rich domain of p53 causes loss of repression and apoptosis induction, but transcriptional activation remains intact (Sakamuro et al., 1997; Venot et al., 1998; Walker and Levine, 1996) .
Histone acetylation and histone deacetylation are involved in the process of chromatin assembly (Jin and Scotto, 1998) . Moreover, histone acetylases (HATs) and histone deacetylases (HDACs) have been found to be associated with the general transcriptional coactivator and corepressor complexes, respectively. HDACs have been proposed to be involved in the mechanism of repression by numerous transcription factors, including Mad/Max, Rb and YY1 (Hassig et al., 1997; Laherty et al., 1997; Luo et al., 1998; Yang et al., 1996) . The presence of HDACs in the corepressor complex has led to the suggestion that transcriptional repression may re¯ect a deacetylation of the adjacent chromatin template (Jin and Scotto, 1998) . Recent studies demonstrated that transcriptional repression by wt-p53 on the promoters of Map4 and stathmin utilizes HDACs, and this interaction is mediated by mSin3a (Murphy et al., 1999) .
Although bcl-2 is subject to both tissue-speci®c and developmental regulation, knowledge about the molecular mechanisms controlling its expression remains limited. It has been suggested that p53 is a negative regulator of bcl-2 expression in lung cancer cells (Miyashita et al., 1994a) and neuronal cells (Budhram-Mahadeo et al., 1999), however, it is not clear what role it plays in B cells. High level expression of p53 in a murine M1 leukemia cell line resulted in decreased bcl-2 expression (Miyashita et al., 1994b) . Mice that lack p53 expression show increased levels of bcl-2 in several dierent tissues, including lymphocytes (Miyashita et al., 1994b; Wang et al., 1997) . In this study, we demonstrate that the bcl-2 promoter is down-regulated by p53 in the DHL-4 B cell line. We mapped the p53 response element to the bcl-2 P2 minimal promoter. Several functional domains of the p53 protein are required for the repression of the bcl-2 promoter, and the interaction between p53 and the TATA binding protein (TBP) is most likely responsible for the repression of the bcl-2 promoter. In addition, bcl-2 promoter activity is increased following treatment with the histone deacetylase inhibitor, trichostatin A (TSA).
Results

Down-regulation of bcl-2 promoter activity by wt-p53
To determine whether p53 plays a role in bcl-2 gene regulation in B cell lymphomas, we used the B-cell line, DHL-4, a human lymphoma cell line with the t(14;18) translocation. Expression of endogenous p53 protein was detected by Western blot analysis. In addition, our sequence analysis showed that mutant p53 was expressed in the DHL-4 cell line. We identi®ed a missense mutation at codon 273 within the mutational hot spot region of the p53 gene. Since a mutant form of p53 was expressed in DHL-4 cells, we also used a p53-null cell line, the human erythroleukemia cell line, K562, in addition to the B-cell line to avoid any confounding eects of mutant p53 expression. Both cell lines were transiently transfected with the full-length bcl-2 promoter construct (containing both the P1 and P2 promoters) and a wt-p53 cDNA expression vector. As shown in Figure 1 , wt-p53 reduced the activity of the bcl-2 promoter by approximately sixfold in DHL-4 cells. A fourfold repression of the bcl-2 promoter by p53 was observed in the K562 cell line. These results demonstrated that wt-p53 was able to down-regulate the bcl-2 promoter in both cell lines. A plasmid with the CMV immediate early promoter was not downregulated by p53 co-expression, so the down-regulation of the bcl-2 promoter was not due to a nonspeci®c eect of p53 on all promoters. In addition, the cells remained viable during this time as determined by trypan blue exclusion, and p53 was able to activate a reporter gene containing consensus p53 binding sites (data not shown).
Identification of the region of the bcl-2 P2 promoter that is responsive to wt-p53
Since the bcl-2 P2 promoter contains a TATA sequence at 790 bp upstream of the translation start site, while the P1 promoter does not, we focused initially on the P2 promoter to investigate the regulation by p53. The bcl-2 P2 promoter deletion constructs used for transient transfection analysis are illustrated in Figure 2a . Among these deletions, the 90 bp construct is a minimal promoter, which contains the TATA sequence and two potential Myb binding sites. We co-transfected the deletion constructs of the bcl-2 P2 promoter with the wt-p53 expression vector or empty expression vector into the DHL-4 cell line. As shown in Figure 2b , wt-p53 caused a signi®cant reduction in luciferase activity of each deletion construct relative to the activity seen in the presence of the empty vector. The minimal promoter was repressed by ®vefold, suggesting that the majority of the repression by p53 was mediated by this region (Figure 2b) . Cotransfection of the bcl-2 P1 promoter with the p53 expression vector showed very little eect (data not shown). Similar results were observed in the K562 cell line ( Figure 2c ).
As described above, the bcl-2 P2 minimal promoter contains a TATA sequence and two potential Myb binding sites. To determine whether the repression by wt-p53 required the Myb binding sites, we cotransfected a bcl-2 P2 promoter construct containing two mutated Myb binding sites and the wt-p53 expression vector into both DHL-4 and K562 cells. Our results showed that the wt-p53-mediated repression of the bcl-2 promoter was independent of the Myb binding sites (data not shown). In addition, with increasing amounts of the wt-p53 expression vector, a dose-dependent decrease in bcl-2 promoter activity was observed in both cell lines. The sequences required for down-regulation by wt-p53 reside within a region encompassing the proximal 90 nucleotides of the bcl-2 P2 promoter, indicating that the TATA sequence itself is likely the target for the repression by wt-p53. Figure 1 Eect of wt-p53 on the activity of the full-length bcl-2 promoter. Transient transfections in DHL-4 cells were performed with the wt-p53 expression vector (striped bars) or the empty expression vector (solid bars) and the full-length bcl-2 promoterluciferase construct at a ratio of 1 : 2. Transfections in K562 cells with wt-p53 expression vector (striped bars) or the empty expression vector (solid bars) and the full-length bcl-2 promoterluciferase construct were performed at a ratio of 1 : 1. The luciferase activity was plotted relative to the minimal promoter activity, which was assigned a value of 100 Interaction of p53 and TBP proteins with the bcl-2 promoter TATA sequence
To determine whether p53 interacted with TBP at the bcl-2 TATA sequence, we prepared nuclear extracts from K562 cells transfected with the wt-p53 expression vector. The nuclear extract was incubated with the biotinylated bcl-2 TATA or mutated TATA oligonucleotide immobilized on strepavidin-coated magnetic beads. After washing the beads, the nuclear proteins bound to the probe were separated by SDS ± PAGE and analysed by Western blot. As expected, TBP bound to the wild-type TATA oligonucleotide but not to the mutated TATA sequence (Figure 3 ). Moreover, p53 was present in the protein complex with the wildtype TATA oligonucleotide but not with the mutated TATA sequence. Since the interaction of p53 with TBP has been described for some other promoters that are repressed by p53 (Seto et al., 1992) , we conclude that the interaction between TBP and p53 most likely contributes to the repression of the bcl-2 promoter.
Association of p53 and TBP with HDAC1/mSin3a in vivo
It has been shown that the transcriptional repression by wt-p53 on the Map4 and stathmin promoters is mediated by HDAC1 and mSin3a in MCF7 breast carcinoma cells (Murphy et al., 1999) . To explore the possibility that this mechanism may be used by p53 to repress the bcl-2 promoter in K562 cells, we searched for the presence of a complex containing p53 and HDAC1/mSin3a. Since we had shown that p53 and TBP interact at the bcl-2 TATA sequence, we also wished to determine whether TBP was present in the HDAC1/mSin3a complex. Our results demonstrated that p53 and TBP were present in a complex that was immunoprecipitated with an antibody speci®c for either mSin3a or for HDAC1 ( Figure 4 , lanes 2,3, respectively). Conversely, HDAC1, mSin3a and TBP were present in immunocomplexes generated using a p53 antibody ( Figure 4 , lane 5). These results suggest that a complex composed of p53, mSin3a, HDAC1 and TBP exists in vivo in K562 erythroleukemia cells transfected with a p53 expression vector.
Interaction of mSin3a with TBP does not require p53
It has been shown that mSin3a interacts with TBP (Wong and Privalsky, 1998). To determine whether mSin3a can interact with TBP at the bcl-2 P2 promoter TATA sequence and to determine if this interaction is dependent on the presence of p53 or TBP, we performed immunodepletion by incubating nuclear extracts from untransfected K562 cells with TBP antibodies. The immunodepleted supernatant was used to test for binding of mSin3a and TBP to the bcl-2 TATA probe. As shown in Figure 5 , no TBP was bound to the wild-type bcl-2 TATA probe when the nuclear extract was depleted with TBP antibodies, whereas TBP binding was detected after treatment of nuclear extracts with an irrelevant antibody (CD40). The same blot was stripped and reprobed with an mSin3a antibody. As shown in Figure 5 , mSin3a was present when TBP was present, but no mSin3a bound to the TATA sequence in the absence of TBP. Our results indicated that the binding of mSin3a to the bcl-2 TATA sequence was dependent on the presence of TBP, but independent of p53.
Treatment with TSA increases bcl-2 promoter activity
To determine whether histone deacetylation plays a role in the regulation of bcl-2 promoter activity and if it involves p53, we examined the eect of trichostatin A (TSA), a potent inhibitor of HDAC activity (Yoshida et al., 1990) . K562 cells co-transfected with p53 or the empty vector with the bcl-2 P2 minimal Figure 3 Characterization of nuclear proteins that bind to the bcl-2 promoter TATA sequence. Nuclear extracts from K562 cells transfected with the p53 vector were incubated with oligonucleotides containing the bcl-2 TATA sequence (TATA) or mutated TATA sequence (TATA mt) conjugated to magnetic beads. The proteins associated with these sequences were separated by SDS ± PAGE. The presence of TBP and p53 was assessed by immunoblotting with antibodies against TBP or p53, respectively. The ®rst lane represents 500 mg of nuclear extract in the absence of oligonucleotide Figure 4 Interactions among p53, TBP, HDAC1, and mSin3a in vivo. Cell lysates from K562 cells transfected with the p53 vector expression were incubated with preimmune serum, anti-mSin3a, anti-HDAC1 and anti-p53 antibodies, respectively. The resulting immunocomplexes were separated by SDS ± PAGE. The blots were probed with antibodies to p53, mSin3a, HDAC1 and TBP promoter construct were incubated in the presence or absence of TSA (100 ng/ml) for 18 h. As shown in Figure 6 , luciferase activity in cells transfected with the empty expression vector increased about ®vefold following TSA treatment. In the presence of TSA, the luciferase activity of cells transfected with the p53 vector was about fourfold higher than in the absence of TSA. These results indicated that TSA was able to stimulate the bcl-2 P2 minimal promoter activity, whether p53 was present or not, and they are consistent with the fact that HDAC/mSin3a can bind to the bcl-2 TATA sequence in the absence of p53. Similar results were observed in the DHL-4 B-cell line (data not shown).
Down-regulation of endogenous bcl-2 mRNA and protein by p53
To determine whether p53 can down-regulate endogenous bcl-2 expression, we utilized K562 cells transfected with p53. As K562 cells express low levels of Bcl-2 protein compared with DHL-4 cells, we performed competitive RT ± PCR to quantitate endogenous bcl-2 mRNA levels. We co-transfected K562 cells with the pHook2 and p53 vectors and selected the transfected cells with magnetic beads coated with hapten. Total RNA was isolated from the transfected cells and competitive RT ± PCR was performed. As seen in Figure 7a ,b, the relative level of bcl-2 mRNA in cells transfected with p53 was about ®vefold lower than that of cells transfected with the empty vector. The eect of TSA treatment was also examined and we found that TSA resulted in a fourfold increase in bcl-2 mRNA level (Figure 7a,b) . In addition, an induction of bcl-2 mRNA was observed in cells transfected with p53 followed by TSA treatment (Figure 7a ,b). The change in the level of endogenous bcl-2 mRNA was similar to the change in bcl-2 promoter activity with each of these treatments. Similar patterns were observed with Bcl-2 protein in DHL-4 cells by Western blot (Figure 7c,d ). Bcl-2 protein was decreased by approximately threefold in cells transfected with p53. It is likely that transcripts initiated at the P1 promoter account for the residual level of bcl-2 protein expression (see Figure 8 ). These results demonstrate that the endogenous bcl-2 mRNA and protein levels can be regulated by p53, and they con®rm the transient transfection results with the bcl-2 promoter.
Selective promoter usage and the effects of p53
Although the bcl-2 P1 (5') promoter is the most active promoter in some B cells, RNase protection assays demonstrated that the P2 (3') promoter was used at almost the same level as the P1 promoter in DHL-4 cells with the translocated bcl-2 gene ( Figure 8, lanes  2,7) . In K562 cells, the P2 promoter is the major promoter ( Figure 8, lanes 4,9) . To further examine the eect of p53 on the expression of endogenous bcl-2, cotransfection studies were performed. Expression of p53 had essentially no eect on transcripts from the 5' bcl-2 promoter ( Figure 8, lanes 2,3) , while there was a sixfold decrease in transcripts from the 3' promoter ( Figure 8, lanes 7,8) . These results are consistent with the results from the reporter gene assays. In the presence of p53, there were no transcripts initiated from the bcl-2 5' promoter in K562 cells, and there was a threefold decrease in transcripts from the 3' promoter ( Figure 8, lanes 9,10) . These studies strengthen the conclusion that p53 acts exclusively through the TATA-containing 3' bcl-2 promoter.
p53 induces apoptosis of DHL-4 cells
Since p53 down-regulates endogenous bcl-2 levels in both K562 and DHL-4 cells, we wanted to explore the Figure 5 TBP and mSin3a form a complex at the bcl-2 promoter TATA sequence in the absence of p53. Nuclear extracts from K562 cells were immunodepleted with antibodies to TBP or with control anti-CD40 antibodies. The immunodepleted supernatant was incubated with oligonucleotides containing the wild-type TATA sequence conjugated to magnetic beads. The proteins associated with these sequences were separated by SDS ± PAGE. The presence of TBP and mSin3a was assessed by immunoblotting with antibodies against TBP or mSin3a, respectively. The bottom panel demonstrates that mSin3a is present in immunodepleted nuclear extracts Figure 6 TSA up-regulates bcl-2 promoter activity whether p53 is present or not. K562 cells were transfected with the bcl-2 minimal promoter construct and the p53 expression vector, and the transfected cells were resuspended in media in the presence or absence of TSA (100 ng/ml) for 18 h. The data were plotted relative to the activity of the bcl-2 promoter with the empty expression vector without TSA treatment physiologic signi®cance of this and determine whether increased apoptosis was observed. DHL-4 cells were transfected with the p53 expression vector or the empty expression vector and the pHook2 vector. Transfected cells were selected at dierent time points and analysed by¯ow cytometry for Annexin V binding. An increase in the number of apoptotic cells was seen at 22 h and later time points (Table 1) .
Requirement of functional domains of p53 for repression of the bcl-2 promoter Multiple activities of p53 have been assigned to dierent regions of the protein (Figure 9a ). The Nterminal transactivation domain and the C-terminus interact with TBP (Horikoshi et al., 1995; Martin et al., 1993) . Previous studies have shown that amino acid residues 22 and 23 in the N-terminal domain are required for transactivation (Horikoshi et al., 1995) . The proline-rich domain seems to be related to growth suppression by p53 (Walker and . The central core is a sequence speci®c DNA-binding domain, and more than 90% of the missense mutations are clustered here (Levine, 1997) . To de®ne the functional domains of the p53 protein required for repression of the bcl-2 promoter, several mutant p53 (mt-p53) expression constructs were used (Figure 9a) . Loss of repression of bcl-2 promoter activity was seen Competitive RT ± PCR analysis of bcl-2 mRNA in K562 cells. K562 cells were transiently transfected with the pHook2 vector and p53 expression vector or the empty vector. TSA treatment was for 18 h. After incubation for 18 h, sFV-expressing cells were selected using hapten-coated magnetic beads. Total RNA was extracted and reversed transcribed into ®rst-strand cDNA. cDNA and competitor DNA were co-ampli®ed, and the concentration of competitor was indicated as copies/ml. (b) RT ± PCR data from three independent experiments. The relative bcl-2 mRNA level was indicated as copies/ml. (c) Immunoblot analysis of Bcl-2 protein levels in DHL-4 cells transfected with p53 and pHook2 and selected as above. Quantitation was performed by phosphorimager analysis. (d) Quantitation of the immunoblot analysis for Bcl-2 protein with three constructs in DHL-4 cells (Figure 9b , columns 3 ± 5). The N-terminal 22,23 mutation repressed the bcl-2 promoter by only 16% compared to the repression observed with wt-p53 (Figure 9b , column 3), and the repression was approximately the same for the mutant lacking the proline-rich domain (15%, Figure 9b , column 4). The mutant p53-175 repressed promoter activity by 31% (Figure 9b , column 5). The three mt-p53 constructs also showed markedly reduced repression of the bcl-2 promoter in K562 cells (Figure 9c , columns 3 ± 5). Our results demonstrate that the N-terminus, proline-rich domain, and amino acid residue 175 are all required for full repression of the bcl-2 promoter by wt-p53. These results provide support for the conclusion that the interaction of p53 and TBP are required for the p53-mediated repression of bcl-2.
The C-terminus of the p53 protein is required for repression of the bcl-2 promoter The C-terminus of the p53 protein contains an oligomerization domain and non-speci®c DNA binding Figure 8 Bcl-2 promoter usage in DHL-4 and K562 cells and the eect of p53 on promoter usage. RNase protection assays were performed with probes that covered the 5' or 3' bcl-2 promoter regions. The transcription start sites that correspond to the protected fragments are indicated. Samples that were electrophoresed for a longer period of time are shown for the 3' probe (labeled upstream). These bands indicate transcripts that initiated upstream at the 5' promoter region. A probe for GAPDH was used as an internal control Per cent increase in apoptotic cells determined by annexin V staining for cells transfected with the p53 expression factor compared to cells transfected with the empty vector Figure 9 The eect of mutant p53 on bcl-2 promoter activity. (a) Schematic representation of the p53 protein and the p53 mutants used for transient transfection experiments. Numbering corresponds to the amino acid sequence. The regions mediating transcriptional activation (amino acids 1 ± 50), sequence-speci®c DNA binding (amino acids 100 ± 290), oligomerization (amino acids 320 ± 360), and non-speci®c DNA binding (amino acids 370 ± 393) are indicated. (b) Activity of p53 mutants on the bcl-2 promoter activity in DHL-4 cells. Cells were co-transfected with expression vectors encoding wt-p53, the double point mutant 22 and 23, the mutant with the proline-rich domain deleted (proAE), the missense mutant-175, C-terminal deletions to amino acid residues 333, 353 and 363, or the empty vector and the bcl-2 P2 minimal promoter-luciferase construct. Activity was plotted relative to the activity in the absence of p53 (100%). (c) Activity of p53 mutants on the bcl-2 promoter activity in K562 cells domain, and it interacts with TBP ( Levine, 1997) . To determine whether the C-terminus of the p53 protein was involved in repression of the bcl-2 promoter, three C-terminal deletions to amino acid residues 363, 353 and 333 were utilized. We co-transfected these Cterminal deletions into DHL-4 cells with the bcl-2 P2 minimal promoter construct (Figure 9b , columns 6 ± 8).
The luciferase activities were about 47 and 52% of the empty vector control when deletions 363 and 353 were transfected. However, the luciferase activity with deletion 333 increased to 102% (Figure 9b, column  8 ). These results demonstrate that the C-terminal deletions to amino acid residues 363 and 353 partially preserved the repression of p53, while the deletion to amino acid 333 relieved most repression. Since the region between deletions 353 and 333 is the oligomerization domain, it appears that the oligomerization domain is necessary for the repression displayed by wtp53. Similar results were observed with the C-terminal deletion constructs of p53 in K562 cells (Figure 9c , columns 6 ± 8). p53 has been shown to form dimeric or tetrameric oligomers (Levine, 1997; Sang et al., 1994) . Moreover, tumor associated p53 mutants can complex with wtp53 (Sang et al., 1994) . To investigate whether mt-p53 could inhibit the ability of wt-p53 to repress bcl-2 gene expression, we performed co-transfection experiments in K562 cells with increasing amounts of mtp53-175 expression vector and a constant amount of wt-p53 expression vector (data not shown). K562 cells were used for these experiments since they do not express endogenous p53. Our results showed that mtp53-175 displayed a dominant negative eect over wt-p53.
Discussion
In these studies, we demonstrated that wt-p53 repressed the bcl-2 promoter in both a B-cell line and a p53-null hematopoietic cell line. Co-transfections with a series of deletions of the bcl-2 P2 promoter in dierent cell lines revealed a p53-responsive element in the bcl-2 P2 minimal promoter. Moreover, repression by wt-p53 of the bcl-2 minimal promoter showed a dose response to increasing amounts of p53. The fact that bcl-2 levels are increased in tissues of p53 null mice suggests that physiologic concentrations of p53 play a role in the regulation of bcl-2 expression. Since we excluded the possibility of the involvement of two potential Myb binding sites within the bcl-2 P2 minimal promoter, it is likely that the interaction of p53 with TBP is responsible for the repression by wtp53 of the bcl-2 promoter. Other studies have shown that expression of wt-p53 reduces the activity of a variety of promoters, including those of the c-fos, bactin, hsp70, c-jun and rb genes (Ginsberg et al., 1991; Shiio et al., 1992) . Thus, p53 seems to display a very broad speci®city. However, the repression is promoterspeci®c, since several promoters including the class I major histocompatibility complex (Ginsberg et al., 1991) and the Ha-ras 1 gene (Aoyama et al., 1992; Chin et al., 1992) are neither activated nor inhibited by wt-p53.
We were able to demonstrate that TBP and p53 were present in the nuclear protein complex that bound to the TATA sequence of the bcl-2 promoter. This supports our transfection results and suggests that the repression of the bcl-2 promoter by p53 is mediated through the TATA sequence. Our observations are consistent with previous studies, which demonstrated that the interaction between p53 TBP is direct and that the complex of TBP and p53 can bind to the TATA sequence (Seto et al., 1992) . It is also of interest to compare our results on the mechanism of p53 repression of bcl-2 in B and erythroleukemia cells with those in neuronal cells. Bcl-2 is regulated in part by the Brn-3a POU family transcription factor in neuronal cells (Smith et al., 1998) . While p53 represses bcl-2 expression in neuronal cells, it was shown that p53 bound to a site adjacent to the Brn-3a protein and that they interacted with each other (Budhram-Mahadeo et al., 1999) . We have demonstrated that the mechanism of action of p53 on the bcl-2 promoter in B and erythroleukemia cells is quite dierent from that in neuronal cells.
It is becoming clear that the bcl-2 5' and 3' promoters show dierent levels of activity in dierent cell types. We found that both promoters were utilized in the DHL-4 B cell line with a translocated bcl-2 allele. Previous studies have shown that the normal bcl-2 allele is silent in cells with a translocation of bcl-2 into the immunoglobulin heavy chain gene locus (Seto et al., 1988) . The 5' promoter is preferentially utilized in some B cells (Seto et al., 1988) . Our studies showed that the 3' promoter was active in K562 myeloid cells. The 3' promoter was also utilized predominantly in neuronal cell lines (Smith et al., 1998) . The molecular mechanisms that dictate promoter usage in the dierent cell types have not been de®ned. The only known tissue-speci®c factor involved in bcl-2 regulation is Brn-3a (Smith et al., 1998) . This transcription factor binds to a region in the 3' promoter and may be responsible for the activity of this promoter in neuronal cells. Further studies are required to explore the mechanisms of dierential promoter usage.
The fact that p53 can down-regulate endogenous bcl-2 mRNA and protein suggests the possibility that one mechanism for p53-induced apoptosis is the inhibition of expression of Bcl-2. We demonstrated that increased apoptosis was observed in DHL-4 cells transfected with wt-p53. Recent evidence suggests that the transcriptional repression function of p53 may be important in mediating apoptosis. The adenovirus E1B 19-kD protein or Bcl-2 abrogated p53-dependent apoptosis by inhibiting p53-mediated transcriptional repression (Shen and Shenk, 1994) . P53 mediates apoptosis by both transactivation of genes that enhance apoptosis, e.g., bax (Miyashita and Reed, 1995) , and repression of genes that inhibit apoptosis, e.g., bcl-2 (Miyashita et al., 1994b) . We found that Bax protein was increased by threefold in DHL-4 cells transfected with p53 (data not shown). Since the ratio of Bcl-2 to Bax may be important in the regulation of apoptosis, these data suggest that the changes in the levels of expression of Bcl-2 and Bax contribute to apoptosis induction by p53 in DHL-4 cells. It is likely that there are other mediators as well, for example, Noxa, a BH3-only member of the Bcl-2 family has been shown to be induced by p53 (Oda et al., 2000) .
Signi®cant progress in understanding the role of HDAC/mSin3a in transcriptional silencing has recently been made. A HDAC/mSin3a complex has been shown to be involved in the transcriptional repression by wildtype p53 of the map4 and stathmin promoters (Murphy et al., 1999) . We showed by immunoprecipitation studies that there are interactions among p53, mSin3a, HDAC, and TBP in K562 erythroleukemia cells. Wong and Privalsky (1998) have shown that transcriptional repression by the SMRT-mSin3 corepressor may be mediated by direct physical interactions between the corepressor complex and the general transcription factors. We demonstrated that TBP was required for the binding of mSin3a to the bcl-2 TATA sequence. Although p53 also interacts with TBP to bind as a complex to the bcl-2 TATA sequence, it is not required for the interaction of mSin3a with TBP.
These studies and the results of TSA treatment suggest that p53 and the HDAC/mSin3a act independently to repress the bcl-2 promoter. Our transfection results showed that TSA could stimulate bcl-2 promoter activity or endogenous bcl-2 mRNA levels whether p53 was present or not in K562 cells. These data demonstrated that the HDAC/mSin3a complex itself may eectively repress the bcl-2 P2 minimal promoter without p53, and that the repression by p53 of the bcl-2 promoter is most likely independent of the HDAC/mSin3a complex.
Distinct regions of p53 have dierent roles in transcriptional modulation (Sang et al., 1994) . It is known that the amino-terminal region of p53 possesses a strong transcriptional activation domain and is required for the interaction with TBP. The loss of repression of the bcl-2 promoter by the p53 mutant with substitutions at position 22 and 23 indicated that the transcriptional activation domain was required for repression. Our results are consistent with other reports of p53-mediated repression (Sang et al., 1994; Subler et al., 1994) and support our hypothesis that the interaction of p53 with TBP is required for the repression of bcl-2. Therefore, it is conceivable that the same N-terminal domain of p53 displays dual functions, transactivation and repression.
The multifunctional carboxy-terminal domain lies between residues 300 ± 393. The C-terminus of p53 can function as an autonomous domain capable of binding non-speci®cally to dierent forms of DNA (Levine, 1997) , and it interacts with TBP (Horikoshi et al., 1995) . Although it is known that the minimal region of p53 necessary for cellular transformation and growth suppression localizes to the oligomerization domain (Shaulian et al., 1992) , the normal role of this domain is not entirely clear. Our results from co-transfection experiments with C-terminal deletion truncations of p53 and the bcl-2 P2 minimal promoter construct provided evidence that the oligomerization domain was also essential for the full repression of the bcl-2 promoter. This observation is in agreement with previous studies (Sang et al., 1994; Subler et al., 1994) , and suggests that transcriptional repression by p53 is mediated by its interaction with TBP. Previous studies have shown that both the N-and C-terminal domains of p53 can bind to TBP in vitro (Horikoshi et al., 1995) . The proline-rich domain of the p53 protein located between amino acids 61 and 94 has been shown to be necessary for growth suppression (Walker and , but it is completely dispensable for transcriptional activation. Our functional analysis demonstrated that removal of the proline-rich domain resulted in a loss of the repression of the bcl-2 P2 promoter by p53. Thus, the proline-rich domain also plays an important role in the repression activity of p53.
A missense mutation at codon 175 is one of the most frequent mutations seen in the DNA binding domain of p53 (Levine, 1997) . This mutant is tumor-derived and demonstrates transforming activity (Levine, 1997) . Our results showed that the p53 mutant-175 is defective in repressing the bcl-2 P2 minimal promoter activity. Similar observations were obtained by Seto et al. (1992) , who showed that the p53 mutant-175 not only failed to repress the adenovirus major late promoter in Hela cells but also failed to interact with TBP. It is possible that a mutation at codon 175 results in a partial loss of the ability to bind TBP and repress transcription.
Increasing evidence suggests that mutation of p53 might inhibit wt-p53 function through a dominant negative eect (Sang et al., 1994; Subler et al., 1994) . The hetero-oligomerization between wild-type and mutant p53 is believed to contribute to the dominant eect of mutant over wild-type p53. Our data suggested that p53 mutant-175 displayed a dominant negative eect on the ability of wt-p53 to inhibit the bcl-2 P2 minimal promoter. However, our results indicated that expression of endogenous mutant p53 in the B cell line seemed to play little role in the repression displayed by exogenous wt-p53 in the transient transfection studies. It is not clear why the p53 mutants constitutively expressed in the B cell line failed to show any obvious dominant negative eect over wt-p53. It is possible that individual hot spot mutants dier in their properties, and they do not necessarily behave in a similar fashion and that some mutants, particularly 273 and 143, can, in some circumstances, adopt wild-type properties regarding DNA-binding and transcriptional function (Ko and Prives, 1996) . It is also possible that the expression of large amounts of wild-type p53 protein in transient transfection assays masks the eects of the endogenous mutant p53 proteins.
Our results suggest that the TATA sequence in the bcl-2 P2 minimal promoter is the target for repression by wt-p53. The interaction between p53 and TBP is most likely responsible for the down-regulation of bcl-2 gene transcription by p53, and we showed that endogenous bcl-2 mRNA and protein are also downregulated by p53. In DHL-4 cells, transcripts from the 3' promoter were decreased in the presence of p53. We also observed that the mechanism of p53 repression of bcl-2 is independent of mSin3a/HDAC1 activity. The lack of functional p53 may provide one mechanism for the up-regulation of bcl-2 expression in B cell lymphomas with mutant p53 or high level expression of MDM2. Other lymphomas show upregulation of bcl-2 expression prior to mutation of p53, and p53 mutation is often involved in the transformation to a higher grade lymphoma. Our results suggest that in hematopoietic cells with wildtype p53, it is likely that p53 plays a role in the regulation of bcl-2 expression.
Materials and methods
Plasmid constructs
The bcl-2 promoter-luciferase constructs have been described previously (Heckman et al., 2000; Ji et al., 1996; Wilson et al., 1996) . To make the bcl-2 P2 minimal promoter construct, a Spe1 site was introduced at nucleotide 790 bp with the Chameleon TM Double-Stranded SiteDirected Mutagenesis Kit (Stratagene). All plasmid sequences were con®rmed by sequencing. The expression vectors encoding wt-p53 and the mutant p53 (mt-p53) constructs are under the control of the cytomegalovirus (CMV) immediate-early promoter. The p53 expression vectors with mutations at amino acid residues 22 and 23 in the N-terminus, the proline-rich domain deletion, and the missense mutation at codon 175 were provided by Dr AJ Levine. The expression vectors encoding p53 C-terminal deletion truncations were provided by Dr JA Pietenpol.
Cell lines and transient transfection
The DHL-4 B cell line has a t(14;18) translocation. K562 is a human erythroleukemia cell line. Transfections were performed as previously described (Heckman et al., 2000; Wilson et al., 1996) on cells in log phase. Cells were washed and resuspended in unsupplemented RPMI medium containing 25 mg/ml DEAE-dextran to a concentration of 2610 7 cells/ml for DHL-4 and 5610 6 cells/ml for K562. A total of 20 ± 25 mg of plasmid DNA was added, and electroporation was carried out with the Bio-Rad Gene Pulser at 320 mV, 975 mF for DHL-4 cells; 280 mV, 950 mF for K562 cells.
Luciferase assays
Cells were harvested 18 h post-transfection. Cell lysis and the luciferase assay were performed as previously described (Heckman et al., 2000; Wilson et al., 1996) . Each transfection was repeated at least four times with at least three dierent DNA preparations. The normalized average values with the standard deviations were plotted.
Isolation of nuclear proteins binding to biotinylated probes
The oligonucleotides used as probes for the binding assay of the TATA sequence in the bcl-2 P2 promoter are shown below with the TATA sequence underlined and the mutated bases in boldface.
Bcl-2 TATA TAGGTGGATTATAACTTCTCTTC ATCCACCTAATATTGAAGAG AAG
Mutated TATA TAGGTGGACGCGTGCTTCTCTTC ATCCACCTGCGCACGAAGAGAAG
Five mg of the sense strand of each sequence was 3'-labeled using terminal deoxynucleotidyl transferase (Stratagene) and biotin-14-dATP (Life Technologies, Inc.). The biotin-labeled sense strands were annealed to 5 mg of their complementary antisense strand and puri®ed over a Sephadex column. The concentration of puri®ed oligos was measured by a 260 nm absorbance measurement, and equal amounts of the annealed bcl-2 TATA and mutated TATA oligos were incubated separately with strepavidin-coated magnetic beads (Promega) for 30 min at room temperature. Coupling of the oligos to the magnetic beads was assessed by absorbance measurement at 260 nm. For the binding reactions, 500 mg of nuclear extract prepared from K562 cells transfected with the p53 expression vector was incubated with 100 ml of bcl-2 TATA or mutated TATA-coupled beads in Buer A (60 mM KCl, 0.01% NP-40, 0.1 mg/ml BSA, 0.1 mg/ml poly(dIdC), 4% Ficoll), 50 mg of bovine serum albumin, and 50 mg of poly(dIdC) for 30 min with slow rotation at room temperature. The beads were then captured by a magnet, washed three times with Buer A, and resuspended in Laemmli buer. The samples were separated on a 10% SDS ± PAGE gel. The separated proteins were electrophoretically transferred onto a nitrocellulose membrane. The blots were incubated in blocking solution consisting of 5% fat free dry milk in PBST (0.1% Tween 20 in PBS) at room temperature for 1 h followed by incubation at room temperature for 1 h with anti-TBP or anti-p53 polyclonal antibodies (FL-393, Santa Cruz Biotech, CA, USA). The blots were then incubated with HRP-conjugated secondary antibody for 1 h and visualized with ECL detection reagents (Amersham).
Immunoprecipitation 2610 7 K562 cells were transfected with the p53 expression vector. After 18 h incubation, cells were harvested and lysed in RIPA buer (50 mM Tris at pH 7.4, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 1% Na deoxycholate). Equal amounts of cell lysate were precleared by incubating with 1 mg of normal rabbit immunoglobulin and 20 ml of protein A-agarose at 48C for 30 min. Equal aliquots of the supernatant were immunoprecipitated with 1 mg of each antibody at 48C for 1 h. The immunocomplexes were then collected by incubation with 20 ml of protein A-agarose overnight. The agarose beads were washed twice in NP-40 buer (20 mM Tris-HCl pH 7.2, 100 mM NaCl, 10% glycerol, 1% NP-40, 1 mM EDTA), followed by two washes in RIPA buer, and then boiled in Laemmli buer. The immunoblotting procedure was performed as described above. When stripping was performed, membranes were submerged in buer (62.5 mM Tris-HCl pH 6.8, 2% SDS, 0.1 M 2-mercaptoethanol) at 708C for 30 min and washed extensively with PBS buer before reblocking and probing.
Immunodepletion
Nuclear extracts from K562 cells were incubated with 20 mg of TBP or CD40 antibodies or without antibody at 48C for 1 h, followed by addition of 20 ml of protein A-agarose with further incubation at 48C for at least 2 h. After centrifugation, supernatants were incubated with TBP or CD40 antibodies again, and the immunodepletion step was repeated ®ve times.
Selection of transfected cells and quantitation of bcl-2 mRNA and protein by competitive reverse transcription-PCR or immunoblotting
We used competitive reverse transcription-PCR to quantitate the endogenous bcl-2 mRNA levels in K562 cells. One set of primers was used to amplify target cDNA and an externally added competitor of known concentration. The primer pair ampli®ed a 550 base-pair fragment from the bcl-2 competitor and a 385 base-pair fragment from the endogenous bcl-2 mRNA. Sense primer: ACTTGTGGCCCAGATAGGCACC-CAG; Antisense primer: CGACTTCGCCGAGATGTC-CAGCCAG. K562 or DHL-4 cells were transiently cotransfected with equal amounts of the wt-p53 expression vector or the empty expression vector and the pHook2 expression vector (Invitrogen). The transfected cells were resuspended in media in the presence or absence of TSA (100 ng/ml). The cells were washed and selected using Capture-Tec magnetic beads (Invitrogen) 18 h after transfection. Total RNA from the selected K562 cells was isolated using the StrataPrep total RNA miniprep kit (Stratagene). The PCR pro®le was 948C, 45 s; 708C, 45 s; 728C, 2 min for 35 cycles, followed by a 7 min ®nal extension at 728C. The amount of mRNA was determined by comparison of the relative intensities of the ampli®ed competitor and bcl-2 bands. Total protein was extracted from the selected DHL-4 cells and analysed by immunoblotting with a Bcl-2 antibody from Santa Cruz Biotechnology. Quantitation was performed with a phosphorimager.
Detection of apoptotic cells by annexin V staining
DHL-4 cells were co-transfected with the pHook2 vector and the p53 expression vector or the empty vector. The transfected cells were selected with magnetic beads as described above and washed in ice-cold culture medium. The cells were resuspended at a concentration of 10 5 ± 10 6 cells/ml. Annexin V-FITC (Immunotech) and propidium iodide were added to the cell suspension. The tube was incubated on ice for 10 min in the dark, and then the cells were analysed by¯ow cytometry.
RNase protection assay
DHL-4 cells and K562 cells were transfected with p53 or the empty expression vector and selection of transfected cells was performed as described. The Ambion RPA kit was used. The probe for the 5' promoter region extended from 71555 to 71286, and the probe for the 3' promoter was from 7195 to +68. A probe for GAPDH was used as an internal control. Antisense probes were prepared by in vitro transcription. The protected fragments were resolved on a denaturing 6% acrylamide gel, and quantitation was performed with a phosphorimager.
